Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jana Shaw

Pediatric Infectious Diseases Watertown, NY Medical Doctor

NPI 1548208820 CMS profile 296383

238 Arsenal St, Ste 503, Watertown, NY 13601

Open in the dashboard

General payments

$345,753

233 records reported · program years 2019–2025

Research payments

$5,200

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jana Shaw of Watertown, NY is reported in the CMS Open Payments database as having received $345,753 across 233 general payments and $5,200 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Pediatric Infectious Diseases profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $169,837 62
2024 General $114,738 86
2024 Research $5,200 3
2023 General $30,900 37
2022 General $7,071 7
2021 General $1,900 1
2020 General $1,900 1
2019 General $19,408 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jana Shaw
  • Pediatric Infectious Diseases median
  • Middle half of Pediatric Infectious Diseases
  • National median

In program year 2025, general payments to Jana Shaw were reported at $169,837. Among 311 Pediatric Infectious Diseases profiles paid that year, the median was $126 and the middle half received between $41 and $2,094.

Show as a table
Year Jana Shaw Pediatric Infectious Diseases median Middle half National median
2019 $19,408 $175 $34–$2,175 $163
2020 $1,900 $521 $34–$6,009 $114
2021 $1,900 $1,077 $39–$4,557 $132
2022 $7,071 $232 $53–$6,196 $149
2023 $30,900 $140 $52–$4,662 $160
2024 $114,738 $198 $52–$3,860 $164
2025 $169,837 $126 $41–$2,094 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $268,269 205 payments
  2. GlaxoSmithKline, LLC. $42,396 21 payments
  3. Pfizer International LLC $23,217 5 payments
  4. Sanofi Pasteur Inc. $11,870 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $133,884 32 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $119,902 45 payments
  3. Travel and Lodging $85,146 106 payments
  4. Food and Beverage $4,945 48 payments
  5. Honoraria $1,875 2 payments
Products named General payments · program years 2019–2025
  1. PREVNAR 20 $107,684 52 payments
  2. PENBRAYA $91,772 83 payments
  3. TRUMENBA $35,805 45 payments
  4. BEXSERO $26,012 3 payments
  5. PREVNAR 13 $23,217 5 payments
  6. SHINGRIX $128 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $5,200 3 payments

Records

236 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Infectious Diseases in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record